Kevin Coker
Kevin Coker, JD, MPH, MS, is innovation strategist and leads MedTech development at MD Anderson Cancer Center, the world’s top-ranked cancer center, and advisor to First Bight Investments, a venture fund/accelerator for synthetic biology and industrial biomanufacturing. Coker cofounded and was CEO of Proxima Clinical Research, a CRO ranked by Inc. Magazine as one of the fastest-growing companies in 2021 and 2022, earning more than 30 awards in its first seven years. He also founded M1MedTech, a virtual venture studio for medical devices, and co-hosted Inventing Tomorrow podcast. Coker has held senior leadership roles across biotech, MedTech, and clinical research, including board director at Volumetric Biotechnologies (acquired by 3D Systems), CEO of MolecularMatch, VP at Worldwide Clinical Trials, and VP, US Oncology Research at McKesson Corp. He holds degrees in biology, pathology, law, and public health and is certified in clinical molecular biology and U.S. regulatory affairs.
ARTICLES BY KEVIN COKER
-
![auditing, evaluating, quality and efficiency of personnel, inspection-GettyImages-1555003816]( "Managing Risk And Resilience In Clinical Trial Supply And Operations")
2/12/2026Clinical leaders are shifting from reactive fixes to deliberate governance and early decision-making to sustain trial continuity under persistent operational uncertainty.
-
![Global health safety regulation-GettyImages-2245658628]( "FDA Staffing Constraints And Operational Risk In Clinical Supply")
2/11/2026FDA staffing shortages and supply pressures are reshaping clinical trials, requiring closer coordination across regulatory, manufacturing, and operations.
-
![Global healthcare, pharmaceutical access-GettyImages-2243381185]( "Tariffs Threaten Clinical Trial Supply Chains: Preparing For Volatility")
2/10/2026Tariffs and FDA staffing gaps are quietly reshaping clinical trial supply chains. From comparators to customs delays, these forces are creating real risk for timelines, budgets, and patients.
